Zacks: Brokerages Anticipate Achillion Pharmaceuticals (ACHN) to Announce -$0.14 Earnings Per Share

Wall Street analysts forecast that Achillion Pharmaceuticals (NASDAQ:ACHN) will post earnings per share (EPS) of ($0.14) for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Achillion Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.13) and the lowest estimate coming in at ($0.14). Achillion Pharmaceuticals posted earnings of ($0.15) per share during the same quarter last year, which would indicate a positive year over year growth rate of 6.7%. The business is scheduled to issue its next quarterly earnings results on Thursday, May 3rd.

According to Zacks, analysts expect that Achillion Pharmaceuticals will report full-year earnings of ($0.55) per share for the current fiscal year, with EPS estimates ranging from ($0.56) to ($0.55). For the next year, analysts expect that the business will post earnings of ($0.59) per share, with EPS estimates ranging from ($0.62) to ($0.51). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that cover Achillion Pharmaceuticals.

How to Become a New Pot Stock Millionaire

Achillion Pharmaceuticals (NASDAQ:ACHN) last released its quarterly earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by ($0.01). During the same period in the previous year, the company earned ($0.03) earnings per share.

Several research firms have recently commented on ACHN. BidaskClub lowered Achillion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, January 13th. B. Riley began coverage on Achillion Pharmaceuticals in a research report on Thursday, February 8th. They issued a “neutral” rating and a $3.50 price target for the company. Zacks Investment Research lowered Achillion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, January 2nd. Finally, Leerink Swann reissued a “buy” rating and issued a $5.00 price target on shares of Achillion Pharmaceuticals in a research report on Monday, December 11th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and three have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $4.89.

Large investors have recently made changes to their positions in the stock. Dimensional Fund Advisors LP increased its position in Achillion Pharmaceuticals by 75.3% during the 3rd quarter. Dimensional Fund Advisors LP now owns 3,276,076 shares of the biopharmaceutical company’s stock valued at $14,710,000 after buying an additional 1,407,108 shares in the last quarter. Matisse Capital increased its position in Achillion Pharmaceuticals by 15.8% during the 4th quarter. Matisse Capital now owns 135,445 shares of the biopharmaceutical company’s stock valued at $390,000 after buying an additional 18,500 shares in the last quarter. BVF Inc. IL acquired a new position in Achillion Pharmaceuticals during the 4th quarter valued at about $4,632,000. Sarissa Capital Management LP acquired a new position in Achillion Pharmaceuticals during the 3rd quarter valued at about $9,594,000. Finally, RTW Investments LP increased its position in Achillion Pharmaceuticals by 72.8% during the 4th quarter. RTW Investments LP now owns 13,546,902 shares of the biopharmaceutical company’s stock valued at $39,015,000 after buying an additional 5,707,136 shares in the last quarter. 82.04% of the stock is currently owned by institutional investors.

ACHN opened at $3.38 on Friday. The firm has a market capitalization of $489.52, a PE ratio of -5.63 and a beta of 0.89. Achillion Pharmaceuticals has a 12 month low of $2.58 and a 12 month high of $5.66.

ILLEGAL ACTIVITY WARNING: This report was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this report on another site, it was stolen and reposted in violation of international copyright & trademark law. The original version of this report can be read at https://ledgergazette.com/2018/04/13/zacks-brokerages-anticipate-achillion-pharmaceuticals-achn-to-announce-0-14-earnings-per-share.html.

Achillion Pharmaceuticals Company Profile

Achillion Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders in the United States. Its lead drug candidate includes ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy.

Get a free copy of the Zacks research report on Achillion Pharmaceuticals (ACHN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply